Digital Breast Tomosynthesis

Digital Breast Tomosynthesis

Global Digital Breast Tomosynthesis Market to Reach US$7.6 Billion by 2030

The global market for Digital Breast Tomosynthesis estimated at US$3.5 Billion in the year 2023, is expected to reach US$7.6 Billion by 2030, growing at a CAGR of 11.7% over the analysis period 2023-2030. 2D / 3D Combination Mammography Systems, one of the segments analyzed in the report, is expected to record a 13.6% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Standalone 3D Mammography Systems segment is estimated at 11.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$948.5 Million While China is Forecast to Grow at 16.1% CAGR

The Digital Breast Tomosynthesis market in the U.S. is estimated at US$948.5 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 16.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.7% and 10.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.4% CAGR.

Global Digital Breast Tomosynthesis Market - Key Trends and Drivers Summarized

Digital Breast Tomosynthesis (DBT), also known as 3D mammography, is a revolutionary imaging technology that improves the accuracy of breast cancer detection and diagnosis. Unlike traditional two-dimensional mammography, DBT captures multiple images of the breast from different angles, creating a layered, three-dimensional reconstruction. This method enhances the radiologist`s ability to identify and characterize breast lesions, reducing the likelihood of false positives and unnecessary biopsies. DBT is particularly beneficial for women with dense breast tissue, where traditional mammography might miss abnormalities. Since its approval by the FDA in 2011, DBT has been increasingly adopted in clinical practice, leading to better patient outcomes and more precise breast cancer screening protocols.

Technological advancements in DBT have significantly contributed to its widespread adoption and effectiveness. Modern DBT systems are equipped with advanced software algorithms that improve image quality and reduce radiation dose. The integration of artificial intelligence (AI) and machine learning into DBT systems further enhances diagnostic accuracy by assisting radiologists in detecting subtle abnormalities and reducing reading times. Additionally, continuous improvements in detector technology and image reconstruction techniques have made DBT a more reliable and efficient tool for breast cancer screening. The combination of these technological advancements ensures that DBT remains at the forefront of breast imaging, offering unparalleled diagnostic capabilities compared to conventional mammography.

The growth in the digital breast tomosynthesis market is driven by several factors. The rising prevalence of breast cancer globally has heightened the demand for more accurate and reliable screening methods, positioning DBT as a preferred choice. Technological innovations, such as AI integration and improved image processing, have expanded the capabilities of DBT systems, making them more effective and user-friendly. Increasing awareness among women about the importance of regular breast cancer screening and the advantages of DBT over traditional methods is also driving market adoption. Moreover, supportive government policies and reimbursement frameworks in many regions are facilitating access to DBT, encouraging healthcare facilities to invest in this advanced technology. Additionally, the growing focus on personalized medicine and patient-centric care is pushing for the adoption of DBT, which offers more detailed and individualized diagnostic information. Collectively, these factors are fueling the rapid expansion and development of the digital breast tomosynthesis market.

Select Competitors (Total 86 Featured) -

• Allengers Medical Systems Ltd.
• Canon Medical Systems Corporation
• FUJIFILM Healthcare Americas Corporation
• GE HealthCare PLC
• Hologic, Inc.
• I.M.S. (Internazionale Medico Scientifica) Srl
• LBN Medical
• Metaltronica SpA
• Planmed Oy
• Shanghai United Imaging Healthcare Co., LTD
• Siemens Healthcare GmbH
• Trivitron Healthcare;

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.